Peptide Cancer Vaccine Market Global Insights, 2018-2026Posted by Pareesh on July 6th, 2018 Peptide cancer vaccines aids to elicit and expand tumor-specific T-cells capable of controlling or eradicating tumor. This vaccine consists of one or more short or long amino acid sequences as tumor antigens, combined with vaccine adjuvant. In the recent past, results of clinical trials performed using peptide cancer vaccine had exhibited negative outcomes. So, researchers in the peptide vaccine have considered this as outdated therapy and declared it as no longer viable for cancer treatment. However, increasing progress in understanding critical role of immune adjuvants, modes of vaccine administration, and T cell dynamics has led to re-emergence of this approach for treating malignant disorders. Click To Continue Reading on Peptide Cancer Vaccine Market North America market accounted for the largest share in the global peptide cancer vaccine market, followed by Europe market in 2016. Furthermore, advantages involved in the preparation and usage of peptide vaccine are easy to synthesize, cost-effective, easy to prepare, and its application in clinical practice, flexibility in changing antigen, and lower risk of antigen-induced anaphylaxis are expected to foster growth of the peptide cancer vaccine market in the near future. Therefore, owing to these advantages, manufacturers are focusing on research, to develop peptide cancer vaccines. For instance, in April 2018, Boston Biomedical, Inc. involved in next generation cancer therapeutics, initiated dosing of the first patient in each of two clinical studies to evaluate the results of its affectability by using DSP-7888, an investigational cancer peptide vaccine. According to a National Cancer Institute, 2016, in the U.S., it was estimated that 16.8 million new cases of cancer were diagnosed with an approximate 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024. Furthermore, the World Health Organization (WHO) reported around 14 million cases of cancer and 8.2 million deaths caused by the disease in 2012. Among these, the common cases pertained to lung, colorectal, prostate, cervical, and breast cancer, which significantly has increased demand for peptide vaccines, in turn aiding in growth of the global peptide cancer vaccine market. Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1634 Key Vendors: TapImmune, Merck, BrightPath Biotherapeutics, Sellas, BioLife Science, Boston Biomedical, VAXON Biotech, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Antigen Express, Immatics Biotechnologies, Immatics, Immune Design, Immunomedics, Galena Biopharma, Generex Biotechnology Corporation, and Ultimovacs. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Mr. Shah Like it? Share it! More by this author |